Lakeshore Biopharma Co Ltd Revenue Growth Rates (LSB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lakeshore Biopharma Co Ltd  (NASDAQ: LSB)
 

LSB's Revenue Growth by Quarter and Year

Lakeshore Biopharma Co Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LSB Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 80.82
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 80.82





LSB Revenue fourth quarter 2024 Y/Y Growth Comment
Lakeshore Biopharma Co Ltd reported decline in Revenue in the fourth quarter 2024 by -19.18% to $ 80.82 millions, from the same quarter in 2023.
This represents worst decline in recent Company history.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue growth. While Lakeshore Biopharma Co Ltd' s Revenue fall of -19.18% ranks overall at the positon no. 2740 in the fourth quarter 2024.


LSB Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December -19.18 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   -19.18 % - - -

Financial Statements
Lakeshore Biopharma Co Ltd's fourth quarter 2024 Revenue $ 80.82 millions LSB's Income Statement
Lakeshore Biopharma Co Ltd's fourth quarter 2023 Revenue $ 100.00 millions Quarterly LSB's Income Statement


LSB Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -19.18 % - - -


Back to LSB Growth rate Comparisons >> Back to LSB Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #368
Overall #2740

Revenue Y/Y Growth Statistics
High Average Low
-19.18 % -19.18 % -19.18 %
(Mar 31 2024)  
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #368
Overall #2740
Revenue Y/Y Growth Statistics
High Average Low
-19.18 % -19.18 % -19.18 %
(Mar 31 2024)  

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Lakeshore Biopharma Co Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LSB's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LSB's IV. Quarter Q/Q Revenue Comment


Lakeshore Biopharma Co Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 85.23 $ 80.82 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 5.45 % -19.18 % - - -
Year on Year Revenue Growth Overall Ranking # 3147 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 5.45 % -19.18 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 3144 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Lakeshore Biopharma Co Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.45% year on year, to $ 85 millions if the fiscal year would have ended in Mar 31 2025.
Lakeshore Biopharma Co Ltd's trailing twelve months Revenue growth was higher than company's average -19.18% and higher than -19.18% growth in Mar 31 2024.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 5.45 % increase from $80.82 millions in the period from Mar 31 2024 to .

In the Healthcare sector 454 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3147.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 165
Healthcare Sector # 455
Overall # 3147

Revenue TTM Y/Y Growth Statistics
High Average Low
-19.18 %
 -19.18 %
-19.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 165
Sector # 453
S&P 500 # 3144
Cumulative Revenue growth Comment
Lakeshore Biopharma Co Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.45% year on year, to $ 85 millions if the fiscal year would have ended in Mar 31 2025.
Lakeshore Biopharma Co Ltd's trailing twelve months Revenue growth was higher than company's average -19.18% and higher than -19.18% growth in Mar 31 2024.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 5.45 % increase from $80.82 millions in the period from Mar 31 2024 to .

In the Healthcare sector 454 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3147.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 165
Healthcare Sector # 455
Overall # 3147

Revenue TTM Y/Y Growth Statistics
High Average Low
-19.18 %
-19.18 %
-19.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 165
Sector # 453
S&P 500 # 3144




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LSB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Adapthealth Corp -0.19%$ -0.185 millions
Bioaffinity Technologies Inc -0.26%$ -0.260 millions
Organon and Co -0.38%$ -0.375 millions
Royalty Pharma Plc-0.41%$ -0.407 millions
Carlisle Companies Incorporated-0.41%$ -0.408 millions
Silo Pharma Inc-0.41%$ -0.409 millions
Shl Telemedicine Ltd-0.52%$ -0.519 millions
Cytek Biosciences Inc -0.59%$ -0.586 millions
Kronos Bio Inc -0.70%$ -0.700 millions
Koninklijke Philips Nv-0.81%$ -0.815 millions
Enhabit Inc -0.92%$ -0.921 millions
Charles River Laboratories International inc -1.08%$ -1.078 millions
Elanco Animal Health Incorporated-1.45%$ -1.449 millions
Illumina Inc -1.60%$ -1.604 millions
Perrigo Company Plc-1.62%$ -1.616 millions
Fonar Corporation-1.72%$ -1.717 millions
Quipt Home Medical Corp -1.90%$ -1.905 millions
Bio rad Laboratories Inc -1.91%$ -1.910 millions
Surmodics Inc -2.06%$ -2.062 millions
Avantor Inc -2.10%$ -2.101 millions
Petvivo Holdings Inc -2.11%$ -2.111 millions
Iridex Corp-2.15%$ -2.153 millions
Assertio Holdings inc -2.43%$ -2.431 millions
Apyx Medical Corp-2.58%$ -2.578 millions
Bioxcel Therapeutics Inc -2.66%$ -2.660 millions
Zynex inc -2.66%$ -2.665 millions
Nrc Health-2.88%$ -2.879 millions
Teladoc Health Inc -3.03%$ -3.033 millions
Orchestra Biomed Holdings Inc -3.44%$ -3.435 millions
Xenetic Biosciences Inc -3.45%$ -3.449 millions


About Lakeshore Biopharma Co Ltd Revenue Growth Rates (LSB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lakeshore Biopharma Co Ltd (CIK 1946399).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-25-069880
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lakeshore Biopharma Co Ltd ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.